COLL vs. IRWD, PCRX, SYRE, GMTX, BLTE, MIRM, LGND, VRNA, XNCR, and MNKD
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Ironwood Pharmaceuticals (IRWD), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Gemini Therapeutics (GMTX), Belite Bio (BLTE), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Verona Pharma (VRNA), Xencor (XNCR), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Collegium Pharmaceutical (NASDAQ:COLL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, Ironwood Pharmaceuticals had 9 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 16 mentions for Ironwood Pharmaceuticals and 7 mentions for Collegium Pharmaceutical. Ironwood Pharmaceuticals' average media sentiment score of 0.75 beat Collegium Pharmaceutical's score of 0.42 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.
Collegium Pharmaceutical presently has a consensus price target of $39.00, suggesting a potential upside of 5.35%. Ironwood Pharmaceuticals has a consensus price target of $19.80, suggesting a potential upside of 144.14%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical has a net margin of 8.50% compared to Ironwood Pharmaceuticals' net margin of -226.37%. Collegium Pharmaceutical's return on equity of 107.39% beat Ironwood Pharmaceuticals' return on equity.
Collegium Pharmaceutical has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Ironwood Pharmaceuticals received 127 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. However, 65.39% of users gave Collegium Pharmaceutical an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
Summary
Collegium Pharmaceutical and Ironwood Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
